Knowledge hub
Articles from the Molekula editorial team
Coverage of chemistry, regulatory updates, methods, supply-chain insight, and product spotlights. New articles published daily.
-
Regulatory
Navigating US Inflation Reduction Act Incentives for Domestic API Manufacturing Supplies
The Inflation Reduction Act (IRA) offers US API manufacturers a domestic‑content tax credit of up to 30% of qualified investment, subject to a $7,500 per employee cap and a minimum 40% domestic‑content threshold. Eligibility hinges on detailed documentation, timing of asset placement, and compliance with IRS and Treasury guidance.
Aug 26, 2026 · 6 min read -
Regulatory
Emerging REACH SVHC Additions in 2026: Impact on Organophosphorus Reagents
From 1 June 2026 the EU REACH candidate list will include three new surface‑treatment agents and five additional substances, several of which are organophosphorus intermediates. These additions trigger registration, communication and possible restriction obligations for manufacturers and users of organophosphorus reagents.
Aug 25, 2026 · 5 min read -
Supplier-news
Buffer and Reducing‑Agent Supply (DTT/TCEP/HEPES/Tris): Sourcing and Quality in 2026
In 2026, DTT and TCEP remain the principal disulphide‑reducing agents, with TCEP offering greater pH stability and longer shelf‑life, while DTT is cheaper but oxidises rapidly. HEPES and Tris buffers are widely available from multiple GMP‑certified manufacturers, with purity specifications of ≥99.5 % and consistent ISO‑9001 compliance. Regulatory frameworks (REACH, USP, EP) continue to dictate documentation and testing requirements.
Aug 24, 2026 · 5 min read -
Supplier-news
Biocatalysis and Enzyme Engineering in Pharma Synthesis: What Is Changing Procurement?
Biocatalysis and enzyme engineering are reshaping pharmaceutical manufacturing, prompting procurement teams to prioritise supplier reliability, regulatory compliance, and sustainability. Procurement now evaluates enzyme activity data, batch‑to‑batch consistency, and life‑cycle impact, while negotiating flexible contracts to accommodate rapid process optimisation.
Aug 23, 2026 · 4 min read -
Supplier-news
Semiconductor‑grade chemical shortages and their knock‑on effects for high‑purity reagents
The semiconductor industry is experiencing a shortage of high‑purity, semiconductor‑grade chemicals due to heightened demand and limited production capacity. This scarcity cascades into biotech and pharmaceutical labs, restricting access to critical reagents and prompting supply‑chain adjustments.
Aug 21, 2026 · 3 min read -
Regulatory
US TSCA/EPA Chemical Review Backlog: What Importers Should Watch in 2026
The US EPA’s TSCA review backlog exceeds 1,500 chemicals, meaning importers will face extended evaluation times, tighter PMN scrutiny and possible SNURs in 2026. Monitoring EPA updates, preparing robust dossiers and aligning with REACH‑equivalent documentation are essential to avoid delays.
Aug 19, 2026 · 4 min read -
Supplier-news
Cold‑chain and biologics logistics pressures shaping reagent and excipient sourcing in 2026
Cold‑chain constraints and the increasing complexity of biologics logistics are driving changes in how reagents and excipients are sourced in 2026. Suppliers must prioritise temperature‑stable grades, regulatory compliance, and supply‑chain resilience to meet tighter stability windows and global distribution demands.
Aug 18, 2026 · 5 min read -
Regulatory
Green solvents replacing DMF, NMP and DCM under tightening REACH SVHC rules
The REACH SVHC list now includes DMF, NMP and DCM, prompting chemists to adopt greener alternatives such as Cyrene, γ‑valerolactone and 2‑MeTHF. These solvents meet performance criteria while reducing toxicity and regulatory burden, facilitating compliance across pharma and fine‑chemical processes.
Aug 17, 2026 · 6 min read -
Applications
Continuous Manufacturing Adoption in Pharma and the Reagents It Shifts Demand For
Continuous manufacturing is increasingly adopted in pharma to improve efficiency, reduce waste and shorten time‑to‑market. It drives higher demand for high‑purity solvents, specialised catalysts, real‑time analytical reagents and robust excipients that meet tighter quality and regulatory specifications.
Aug 8, 2026 · 6 min read -
Supplier-news
GLP‑1 demand and the specialty‑chemical squeeze for peptide synthesis reagents
GLP‑1 analogue sales surpassed $10 bn in 2023, driving a sharp rise in peptide manufacturing. This surge strains the supply of high‑purity reagents such as Fmoc‑protected amino acids and coupling agents, leading to longer lead times and price increases across the specialty‑chemical market.
Aug 7, 2026 · 4 min read -
Supplier-news
China and India API Manufacturing Shifts in 2026 and Their Implications for Western Procurement
By 2026, China is expected to reduce its share of global API output to around 30% from 45% in 2022, while India aims to increase capacity by 20‑25% to meet rising demand. These shifts will pressure Western buyers to diversify supply chains, reassess risk matrices, and adopt stricter quality‑by‑design controls.
Aug 6, 2026 · 5 min read -
Regulatory
Nitrosamine impurity controls in pharma APIs: current regulatory expectations
Regulators now require systematic risk assessment, strict limits (typically 0.5 ppm or lower) and validated analytical methods for nitrosamines in pharmaceutical APIs. Compliance hinges on ICH M7 guidance, FDA and EMA specific limits, and robust control strategies throughout synthesis and storage.
Aug 5, 2026 · 4 min read